Loading…
for educational and safety purposes
3-MeO-PCP and 4-MeO-PCP both come up in the same conversations; they overlap on Glutamate. 3-MeO-PCP: 3-MeO-PCP (3-methoxyphencyclidine) is a dissociative new psychoactive substance of the arylcyclohexylamine (phencyclidine) class. 4-MeO-PCP: 4-MeO-PCP (4-methoxyphencyclidine) is a methoxy-substituted analog of phencyclidine presumed to act as an NMDA-receptor antagonist, and it is generally regarded as less potent than PCP or the isomeric 3-MeO-PCP, with users reporting a more subtle, functional dissociation.
3-MeO-PCP (3-methoxyphencyclidine) is a dissociative new psychoactive substance of the arylcyclohexylamine (phencyclidine) class. It acts principally as an antagonist at the N-methyl-D-aspartate (NMDA) glutamate receptor and is additionally reported to inhibit monoamine reuptake, giving it a more stimulating and dopaminergic character than ketamine; the closely related analogs 4-MeO-PCP and 3-MeO-PCMo have been shown to engage the mesolimbic dopamine pathway to produce rewarding and reinforcing effects. It is considerably more potent and longer-acting than ketamine, which contributes to a narrow margin between recreational and toxic exposure. The compound has been implicated in numerous non-fatal intoxications and deaths, and its metabolism and analytical detection have been characterized in forensic casework and in silico ADME studies. Because standard phencyclidine immunoassays detect it inconsistently, laboratory confirmation generally relies on chromatographic and mass-spectrometric methods.
4-MeO-PCP (4-methoxyphencyclidine) is a methoxy-substituted analog of phencyclidine presumed to act as an NMDA-receptor antagonist, and it is generally regarded as less potent than PCP or the isomeric 3-MeO-PCP, with users reporting a more subtle, functional dissociation. In silico ADME modeling predicts high gastrointestinal absorption, blood-brain-barrier penetration, extensive tissue distribution, and metabolism dominated by CYP-mediated O-demethylation to phenolic metabolites followed by glucuronidation. Emergency-department case series from the Swedish STRIDA project confirmed analytically verified intoxications, which resembled those of other dissociatives such as PCP, ketamine, and methoxetamine and frequently featured hypertension, tachycardia, and altered mental status, though polysubstance use was common. It cross-reacts with commercial PCP immunoassays and remains an obscure research chemical with limited dedicated human data.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
antagonist
Antagonist
reuptake inhibitor
agonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.